Education
About Us
Working with TipRanks
Follow Us
Kronos Bio, Inc. (KRON)
:KRON
KRON Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kronos Bio News
KRON FAQ
What was Kronos Bio, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Kronos Bio, Inc.’s market cap?
Currently, no data Available
When is Kronos Bio, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kronos Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Kronos Bio, Inc. overvalued?
According to Wall Street analysts Kronos Bio, Inc.’s price is currently Undervalued.
Does Kronos Bio, Inc. pay dividends?
Kronos Bio, Inc. does not currently pay dividends.
What is Kronos Bio, Inc.’s EPS estimate?
Kronos Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kronos Bio, Inc. have?
Currently, no data Available
What happened to Kronos Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kronos Bio, Inc.?
Currently, no hedge funds are holding shares in KRON
Company Description
Kronos Bio, Inc.
Kronos Bio, Inc. (KRON) is a biotechnology company dedicated to discovering and developing novel cancer therapeutics. With a focus on targeting dysregulated transcription, Kronos Bio aims to address difficult-to-treat cancers by exploiting transcriptional dependencies. The company's pipeline includes small molecule therapies designed to modulate transcription factors, which are often implicated in cancer progression.
Kronos Bio (KRON) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Verrica Pharmaceuticals
―
Sutro Biopharma
―
Serina Therapeutics
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Ownership Overview
―
Insiders
3.33%
Mutual Funds
― Other Institutional Investors
96.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---